The latest study from the Jill Roberts Institute, "The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation," was published on September 6 in Nature. To read more, click here.     Dr. Gregory Sonnenberg wins inaugural award from the Society for Mucosal Immunology. To read more, click here.  The Kenneth Rainin Foundation awarded Dr. Iliyan Iliev and colleagues from Mount Sinai a $250,000 Synergy Award to examine the composition of the fungal community in babies born to mothers with inflammatory bowel disease. To read more, click here. Dr. Randy Longman received the Irma T. Hirschl Career Scientist Award and the New York Crohn’s Foundation Award.    

The Jill Roberts Institute for Research in Inflammatory Bowel Disease

You are here

Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes.

TitleScreening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes.
Publication TypeJournal Article
Year of Publication1998
AuthorsCiborowski, P, Konitzki, WM, Blander, JM, Finn, OJ
JournalTumour Biol
Volume19 Suppl 1
Pagination147-51
Date Published1998
ISSN1010-4283
KeywordsAntibodies, Monoclonal, Ascites, Baculoviridae, Blotting, Western, Cytotoxicity, Immunologic, Electrophoresis, Polyacrylamide Gel, Genetic Vectors, Glycosylation, Humans, Mucin-1, Recombinant Fusion Proteins, T-Lymphocytes, Cytotoxic
Abstract

We report the results of a panel of 56 monoclonal antibodies submitted to the ISOBM TD-4 Workshop for the study of the epithelial MUC1 mucin. We used three forms of the MUC1 as antigen. One form of mucin was the native, highly glycosylated MUC1 isolated from the ascites of breast or pancreatic cancer patients. Two other forms of the mucin were recombinantly expressed in a baculovirus expression system as either fully glycosylated, or underglycosylated. Based on the results of Western blot analysis we were able to group the antibodies into 7 clusters depending on their recognition of the MUC1 forms tested. We then selected several antibodies, representatives of each cluster, to test for the ability to block MUC1-specific cytotoxic T-lymphocyte (CTL) function. We found that antibodies ISOBM-163 and ISOBM-147 blocked cytotoxicity of MUC1-specific CTL against two tumor targets in a concentration-dependent manner.

Alternate JournalTumour Biol.
PubMed ID9422100